M
M. Moscovici
Researcher at Bayer
Publications - 13
Citations - 12316
M. Moscovici is an academic researcher from Bayer. The author has contributed to research in topics: Sorafenib & Hepatocellular carcinoma. The author has an hindex of 12, co-authored 13 publications receiving 10489 citations. Previous affiliations of M. Moscovici include Bayer HealthCare Pharmaceuticals.
Papers
More filters
Journal ArticleDOI
Sorafenib in Advanced Hepatocellular Carcinoma
Josep M. Llovet,Sergio Ricci,Vincenzo Mazzaferro,Philip Hilgard,Edward Gane,Jean-Frédéric Blanc,André Cosme de Oliveira,Armando Santoro,Jean-Luc Raoul,Alejandro Forner,Myron Schwartz,Camillo Porta,Stefan Zeuzem,Luigi Bolondi,Tim F. Greten,Peter R. Galle,Jean Francois Seitz,Ivan Borbath,Dieter Häussinger,Tom Giannaris,Minghua Shan,M. Moscovici,D. Voliotis,Jordi Bruix +23 more
TL;DR: In patients with advanced hepatocellular carcinoma, median survival and the time to radiologic progression were nearly 3 months longer for patients treated with sorafenib than for those given placebo.
Journal ArticleDOI
Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Ghassan K. Abou-Alfa,Lawrence H. Schwartz,Sergio Ricci,Dino Amadori,Armando Santoro,Arie Figer,Jacques De Greve,Jean-Yves Douillard,Chetan Lathia,Brian Schwartz,Ian Taylor,M. Moscovici,Leonard B. Saltz +12 more
TL;DR: Although single-agent sorafenib has modest efficacy in HCC, the manageable toxicity and mechanisms of action support a role for combination regimens with other anticancer agents.
Journal ArticleDOI
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.
Jordi Bruix,Jean-Luc Raoul,Morris Sherman,Vincenzo Mazzaferro,Luigi Bolondi,Antonio Craxì,Peter R. Galle,Armando Santoro,Michel Beaugrand,Angelo Sangiovanni,Camillo Porta,Guido Gerken,Jorge A. Marrero,Andrea Nadel,Michael Shan,M. Moscovici,D. Voliotis,Josep M. Llovet +17 more
TL;DR: The SHARP trial as discussed by the authors showed that sorafenib consistently improved median OS and DCR compared with placebo in patients with advanced HCC, irrespective of disease etiology, baseline tumor burden, performance status, tumor stage and prior therapy.
Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B Cirrhosis.
Ghassan K. Abou-Alfa,Dino Amadori,Armando Santoro,Arie Figer,Jacques De Greve,Chetan Lathia,D. Voliotis,Sibyl Anderson,M. Moscovici,Sergio Ricci +9 more
TL;DR: As expected, outcome was poorer in patients with CP B than in those with CP A cirrhosis, and hyperbilirubinemia seen in both groups may be at least partly related to inhibition of UGT1A1 by sorafenib.
Journal ArticleDOI
Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses.
Jean-Luc Raoul,Jordi Bruix,Tim F. Greten,Morris Sherman,Vincenzo Mazzaferro,Philip Hilgard,Hans Scherübl,Max E. Scheulen,Georgios Germanidis,Sophie Dominguez,Sergio Ricci,Andrea Nadel,M. Moscovici,D. Voliotis,Josep M. Llovet +14 more
TL;DR: It is suggested that sorafenib is safe and effective for hepatocellular carcinoma, irrespective of baseline alanine aminotransferase/aspartate aminotsferase, alpha-fetoprotein, or bilirubin concentration and that hepatic function remains stable over the course of sorafanib therapy.